Enasidenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia With an IDH2 Gene Mutation
Status:
Withdrawn
Trial end date:
2022-11-19
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well enasidenib works in treating in patients with acute
myeloid leukemia with an IDH2 gene mutation that has come back or has not responded to
treatment. Enasidenib may stop the growth of cancer cells by blocking some of the enzymes
needed for cell growth. In this study we are investing if enasidenib can be used as
maintenance therapy post salvage induction chemotherapy.